Y-mAbs Therapeutics price target lowered to $14 from $17 at BofA
BofA lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $14 from $17 and keeps a Neutral rating on the shares. While political and rate uncertainty continues to be an overhang, the firm ...